Browsing by Author Rosell, Rafael Costa

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 4 of 4
Issue DateTitleAuthor(s)Citation
2017Gefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survivalDavies, Lucy; Gebski, Val; Lee, Chee Khoon; Lord, Sarah (Sally); Marschner, Ian; Fukuoka, Masahiro; Gralla, Richard J; Inoue, Akira; Mitsudomi, Tetsuya; Mok, Tony; Nakagawa, Kazuhiko; Rosell, Rafael Costa; Thongprasert, Sumitra; Tu, Yu-Kang; Wu, Yi-long; Yang, James; Zhou, Caicun; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials CentreGefitinib or erlotinib vs chemotherapy for EGFR mutation-positive lung cancer: individual patient data meta-analysis of overall survival, Journal of the National Cancer Institute, vol.109, 6, 2017,pp 1-13
2015Impact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-AnalysisDing, Pei Ni; Gebski, Val; Lee, Chee Khoon; Lord, Sarah (Sally); Pavlakis, Nick; Gralla, Richard J; Inoue, Akira; Links, Matthew; Mitsudomi, Tetsuya; Rosell, Rafael Costa; Wu, Yi-long; Yang, James Chic-Hsin; Zhou, Ci-Xiang; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; NH&MRC Clinical Trials Centre; Northern Clinical School: MedicineImpact of Specific Epidermal Growth Factor Receptor (EGFR) Mutations and Clinical Characteristics on Outcomes After Treatment With EGFR Tyrosine Kinase Inhibitors Versus Chemotherapy in EGFR-Mutant Lung Cancer: A Meta-Analysis, Journal of Clinical Oncology, vol.33, 17, 2015,pp 1958-1965
2012Randomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung CancerBoyer, Michael; Barrios, Carlos; Blackhall, Fiona; Bover, Isabel; et al, Various; Frank, Richard; Heo, Dae Seog; Krzakowski, Maciej; Park, Keunchil; Ramalingam, Suresh; Rosell, Rafael Costa; Talbot, Denis; Central Clinical School: MedicineRandomized Phase II Study of Dacomitinib (PF-00299804), an Irreversible Pan–Human Epidermal Growth Factor Receptor Inhibitor, Versus Erlotinib in Patients With Advanced Non–Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.30, 27, 2012,pp 3337-3344
2011Randomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung CancerBoyer, Michael; Bajetta, Emilio; Benner, Rebecca J.; Eberhardt, Wilfried E. E.; et al, various; Hirsh, V; Paz-Ares, Luis; Raats, Johannes; Reiterer, Pavel; Rosell, Rafael Costa; Saleh, Mansoor; Szczesna, Aleksandra; Webb, Roy T.; Central Clinical School: MedicineRandomized Phase III Trial of Paclitaxel/Carboplatin With or Without PF-3512676 (Toll-Like Receptor 9 Agonist) As First-Line Treatment for Advanced Non–Small-Cell Lung Cancer, Journal of Clinical Oncology, vol.29, 19, 2011,pp 2667-2674